+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Immunotherapy Drug Discovery Outsourcing Market Analysis Report By Drug, By Service, By Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Pancreatic), And Segment Forecasts, 2018 - 2025

  • ID: 4751822
  • Report
  • November 2018
  • Region: Global
  • 95 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Aquila Biomedical
  • BPS Biosciences Inc.
  • Celentyx Ltd.
  • Covance, Inc.
  • Crown Bioscience Inc.
  • Explicit Immuno-Oncology
  • MORE
The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025, rising at a CAGR of 13.5% during the forecast period. Increasing prevalence of cancer and rising mortality associated with cancer, along with growing development in the field of cancer immunotherapy, are anticipated to stimulate the growth of the market.

In order to maintain pace with increasing competition in the cancer therapeutics industry, pharmaceutical companies spend 2.5% more than other high tech industries in the in-house R&D. Hence, they are swiftly shifting towards outsourcing of drug discovery in order to achieve lower in-house R&D costs.

Additionally, favorable tax credit allows pharmaceutical companies to appropriately plan their global projects with a reputed CRO and therefore, receive benefits and reduce problems associated with taxation authorities or other bodies administering such incentive programs.

Several new molecules for cancer immunotherapy and new immunotherapeutic options, such as tumor infiltrating lymphocytes, check point inhibitors immunomodulators, and CAR-T cell therapy, have been introduced. Some are in the pipeline and are being tested for their ability to provide better cancer treatment

Further Key Findings From the Report Suggest:
  • Monoclonal antibodies emerged as the largest segment in 2017 because of increasing regulatory approvals and higher efficacy
  • Target identification and validation accounted for the largest share in the global market owing to higher costs incurred and increased investments in new drug development
  • North America dominated the market with the largest share in 2017. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period
  • Some of the key players are Covance, Inc.; Explicyte; Aquila BioMedical; Horizon Discovery Group PLC; Crown Bioscience, Inc.; Promega Corporation; HD Biosciences Co., Ltd.; BPS Bioscience, Inc.; Genscript Biotech Corporation; DiscoverX Corporation; Celentyx Ltd.; ImmunXperts SA; Personalis, Inc.; STC Biologics; and Molecular Imaging, Inc. dominated the cancer immunotherapy drug discovery outsourcing market.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aquila Biomedical
  • BPS Biosciences Inc.
  • Celentyx Ltd.
  • Covance, Inc.
  • Crown Bioscience Inc.
  • Explicit Immuno-Oncology
  • MORE
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope and Assumptions

Chapter 2 Executive Summary
2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation

Chapter 4 Industry Outlook
4.1 Market Variable Analysis
4.1.1 Increasing in-house R & D costs
4.1.2 Increasing adoption of advanced technologies
4.1.3 Mergers and acquisitions
4.1.4 Tax credit
4.2 Market Restraint Analysis
4.2.1 Quality issues involved with drug discovery cro services
4.2.2 Intellectual property right issues
4.3 Porter’s Five Forces Analysis

Chapter 5 Drug Type Business Analysis
5.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Drug Movement Analysis
5.2 Monoclonal Antibodies
5.2.1 Monoclonal antibodies market estimates and forecast, 2014 - 2025
5.3 Immunomodulators
5.3.1 Immunomodulators market estimates and forecast, 2014 - 2025
5.4 Cancer Vaccines and Oncolytic Therapies
5.4.1 Cancer vaccines and oncolytic therapies market estimates and forecast, 2014 - 2025
5.5 Others
5.5.1 Others market estimates and forecast, 2014 - 2025

Chapter 6 Service Business Analysis
6.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: service Movement Analysis
6.2 Target Identification and Validation
6.2.1 Target identification and validation market estimates and forecast, 2014 - 2025
6.3 Lead screening and Characterization
6.3.1 Lead screening and characterization market estimates and forecast, 2014 - 2025
6.4 Cell based Assays
6.4.1 Cell based assays market estimates and forecast, 2014 - 2025

Chapter 7 Cancer Business Analysis
7.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Cancer Movement Analysis
7.2 Lung Cancer
7.2.1 Lung cancer market estimates and forecast, 2014 - 2025
7.3 Breast Cancer
7.3.1 Breast cancer market estimates and forecast, 2014 - 2025
7.4 Colorectal Cancer
7.4.1 Colorectal cancer market estimates and forecast, 2014 - 2025
7.5 Melanoma
7.5.1 Melanoma market estimates and forecast, 2014 - 2025
7.6 Prostate Cancer
7.6.1 Prostate cancer market estimates and forecast, 2014 - 2025
7.7 Head and Neck Cancer
7.7.1 Head and neck cancer market estimates and forecast, 2014 - 2025
7.8 Ovarian Cancer
7.8.1 Ovarian cancer market estimates and forecast, 2014 - 2025
7.9 Pancreatic Cancer
7.9.1 Pancreatic cancer market estimates and forecast, 2014 - 2025

Chapter 8 Regional Business Analysis
8.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Regional Movement Analysis
8.2 North America
8.2.1 North America market estimates and forecast, 2014 - 2025
8.2.2 U.S.
8.2.2.1 U.S. market estimates and forecast, 2014 - 2025
8.2.3 Canada
8.2.3.1 Canada market estimates and forecast, 2014 - 2025
8.3 Europe
8.3.1 Europe market estimates and forecast, 2014 - 2025
8.3.2 Germany
8.3.2.1 Germany market estimates and forecast, 2014 - 2025
8.3.3 UK
8.3.3.1 UK market estimates and forecast, 2014 - 2025
8.4 Asia Pacific
8.4.1 Asia Pacific market estimates and forecast, 2014 - 2025
8.4.2 India
8.4.2.1 India market estimates and forecast, 2014 - 2025
8.4.3 China
8.4.3.1 China market estimates and forecast, 2014 - 2025
8.5 Latin America
8.5.1 Latin America market estimates and forecast, 2014 - 2025
8.5.2 Brazil
8.5.2.1 Brazil market estimates and forecast, 2014 - 2025
8.5.3 Mexico
8.5.3.1 Mexico market estimates and forecast, 2014 - 2025
8.6 Middle East & Africa
8.6.1 Middle east and Africa market estimates and forecast, 2014 - 2025
8.6.2 South Africa
8.6.2.1 South Africa market estimates and forecast, 2014 - 2025

Chapter 9 Company Profile
9.1 Strategy Framework
9.2 Explicit Immuno-Oncology
9.2.1 Company overview
9.2.2 SWOT analysis
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.3 Aquila Biomedical
9.3.1 Company overview
9.3.2 SWOT analysis
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.4 Horizon Discovery Group plc
9.4.1 Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Crown Bioscience Inc.
9.5.1 Company overview
9.5.2 SWOT analysis
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.6 Promega Corporation
9.6.1 Company overview
9.6.2 SWOT analysis
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.7 HD Biosciences Co. Ltd.
9.7.1 Company overview
9.7.2 SWOT analysis
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.8 BPS Biosciences Inc.
9.8.1 Company overview
9.8.2 SWOT analysis
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.9 Gen script Biotech Corporation
9.9.1 Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Celentyx Ltd.
9.10.1 Company overview
9.10.2 SWOT analysis
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.11 ImmuneXperts SA
9.11.1 Company overview
9.11.2 SWOT analysis
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.12 Personalis
9.12.1 Company overview
9.12.2 Product benchmarking
9.12.3 Strategic initiatives
9.12.4 SWOT analysis
9.13 STC Biologics
9.13.1 Company overview
9.13.2 SWOT analysis
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.14 Molecular Imaging Inc. (MI Bioresearch Inc.)
9.14.1 Company overview
9.14.2 SWOT analysis
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.15 Covance, Inc.
9.15.1 Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 Swot analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Explicit Immuno-Oncology
  • Aquila Biomedical
  • Horizon Discovery Group plc
  • Crown Bioscience Inc.
  • Promega Corporation
  • HD Biosciences Co. Ltd.
  • BPS Biosciences Inc.
  • Gen script Biotech Corporation
  • Celentyx Ltd.
  • ImmuneXperts SA
  • Personalis
  • STC Biologics
  • Molecular Imaging Inc. (MI Bioresearch Inc.)
  • Covance, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll